Rituximab for myasthenia gravis in people with moderate symptoms
Treatments studied
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This Phase 3 trial tests rituximab (an immune system medicine) to see if it improves myasthenia gravis (MG) symptoms and function. It’s for adults with confirmed MG and moderate-to-severe impact on daily activities despite current care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have MG confirmed by a blood test for either anti-AChR or anti-MuSK antibodies
- Your MG tests or history suggest your nerve–muscle signaling is abnormal (or you have a typical MG picture that fits, without another cause)
- Your MG severity at screening must be Class II, III, or IV
- Your symptom scores must be at least 5 on MG-ADL (with more than half from non-eye symptoms) and at least 11 on QMG
- You must be willing and able to follow the study schedule and visits
- If you can become pregnant or have a pregnancy-capable partner, you must use highly effective birth control the whole study and for a period after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether tocilizumab can improve symptoms and safety in people with generalized myasthenia gravis (MG) who already take standard MG treatments. It may help if your weakness is still significant despite current therapy.
This study tests whether a new drug called claseprubart can help adults with generalized myasthenia gravis (a condition where muscles get weak and tired easily). The drug works by targeting part of the immune system that damages muscles.
This study tests a new drug called aritinercept to see if it can help people with generalized myasthenia gravis (a condition where muscles weaken over time). Researchers believe this drug may reduce the immune system activity that causes muscle weakness.
This trial tests an early treatment with ravulizumab (a medication that blocks part of the immune system) for people who have recently developed moderate-to-severe generalized myasthenia gravis. The goal is to see if starting treatment early can improve symptoms and daily life.
This trial tests a new medicine, ripertamab, for people with generalized myasthenia gravis (gMG). It aims to see if targeting certain immune cells can help reduce symptoms like muscle weakness.
This trial tests a new medication (remibrutinib) versus a placebo to see if it helps adults with generalized myasthenia gravis. You may qualify if your symptoms affect multiple parts of your body and you haven't had certain recent treatments.
Hear when a new Myasthenia Gravis, Generalized trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.